
HotHouse Therapeutics is a biotech company that leverages a novel plant expression platform and advanced AI/ML techniques to unlock high-value natural and new-to-nature chemistry from plants. Their innovative approach focuses on improving human health by developing therapeutics derived from the rich biosynthetic pathways of over 400,000 plant species. By repurposing plant instructions into bespoke biosynthetic pathways, they create both known and novel compounds that address unmet medical needs. With a commitment to optimizing natural product-based drug discovery, HotHouse Therapeutics aims to revolutionize pharmaceutical development through their unique technology.

HotHouse Therapeutics is a biotech company that leverages a novel plant expression platform and advanced AI/ML techniques to unlock high-value natural and new-to-nature chemistry from plants. Their innovative approach focuses on improving human health by developing therapeutics derived from the rich biosynthetic pathways of over 400,000 plant species. By repurposing plant instructions into bespoke biosynthetic pathways, they create both known and novel compounds that address unmet medical needs. With a commitment to optimizing natural product-based drug discovery, HotHouse Therapeutics aims to revolutionize pharmaceutical development through their unique technology.
Founded: 2020
Headquarters: Norwich, England
Industry: Biotechnology
Technology: AI-driven plant expression platform (BotanAI & BotanBio)
Recent funding: £2.9M pre-seed (announced Dec 2, 2025)
Natural product-based drug discovery and sustainable production of complex small molecules and adjuvants.
2020
Biotechnology
£2.9M
Reported investors include SynBioVen, Start Codon, UKI2S, Twin Path Ventures, Wren Capital, angel investors, and an Innovate UK grant.
“SynBioVen; Start Codon; UKI2S; Twin Path Ventures; Wren Capital”